First Addendum to Roche/CombiMatrix Research and Development Agreement

Contract Categories: Business Operations › Development Agreements
Summary

CombiMatrix Corporation and Roche Diagnostics GmbH have agreed to update their existing Research and Development Agreement by revising Annex I. This addendum updates project milestones, committee priorities, and includes completed milestones for accuracy. Both parties have agreed to substitute the revised Annex I, which details the development program and payment schedule. Some information in the annex has been omitted for confidentiality. The addendum is effective upon signature by both parties.

Read More Arrow
EX-10.17 3 firstamend-roche.htm FIRST ADDENDUM TO ROCHE AGREEMENT First Addendum to Roche Agreement
EXHIBIT 10.17
 
cbmx
COMBIMATRIX
CORPORATION

6500 Harbour Heights Pkwy
Muklteo, WA 98275

Tel ###-###-####
Fax ###-###-####

www.combimatrix.com

Via Overnight Courier
25 March 2003
Stefan Willemsen
Roche Diagnostics GmbH
Nonenwald 2
82377 Penzberg
Germany

First Addendum to Roche/CBMX Research and Development Agreement

Dear Stefan:
As we discussed, we need to update Annex I in the current R&D Agreement to update the project milestones and priorities of the Committee and to add in completed milestones for the sake of completeness.

Please sign both copies of this letter with a revised Annex I to substitute in the revised Annex I.

Sincerely,
Combimatrix Corporation
 
/s/ Jeff Oster
 
Jeff Oster
Sr. Vice President for Intellectual Property

Agreed to substitute revised Annex I
Roche Diagnostics GmbH
 
/s/ Stefan Willemsen
Stefan Willemsen
 

Annex I
Development Program and Payment Schedule


A  1 K System
        
 
 Product  Due Date  Deliverable
Milestone Payment 
In Mio US $
*
 
*
*
 
*
 
 
 
 
*
 
 
 
 
 
 
 
 
 
 
 
*
 
 
 
 
 
 
 
 
 
 
*
 
 
*
 
 
*
 
 
 
*
 
 
 
 
 
 
*
 
 
 
 
 
 
*
 
 
*
 
 
*
 
 
 
*
 
 
 
 
 
 
*
 
 
*
 
 
 
 
 
*
 
 
 
*
 
 
 
 
 
 
 
*
 
* Omitted pursuant to a request for confidential treatment. The omitted material has been filed separately with the SEC.
 
*
 
 
 
 
*
 
 
 
 
 
 
*
 
*
 
 
 
 
 
 
*
 
 
*
 
 
 
 
 
*
*
 
 
 
 
*
 
 
 
*
 
 
 
*
 
 
 
*
 
 
 
 
 
 
 
 
*
 
 
 
*
 
 
 
*
 
 
 
*
 
 
 
*
 
 
 
*
 
 
 
 
 
 
 
*
 
*
 
 
 
*
 
 
*
 
  
 
*
 
 
 
 
*
 
 
 
*
 
 
 
 
*
 
 
 
*
*
 
 
 
 
 
 
 
 
*
*
 
* Omitted pursuant to a request for confidential treatment. The omitted material has been filed separately with the SEC.
 
*
*
*
 
 
*
 
*
 
*
 
 
 
*
*
 
 
 
*
 
 
 
*
 
*
 
 
 
*
 
 


B

10 K System and other development projects

*
 
*
*
 
 
*
 
 
*
 
 
 
*
*
 
 
*
*
 
 
 
*
*
 
  
*
 
*
 
 
*
*
 
 
*
 
  

* Omitted pursuant to a request for confidential treatment. The omitted material has been filed separately with the SEC.